Would it surprise anyone to see that Seeking Alpha
Post# of 72440
Here's what "APBK Capital" said in the article:
Quote:
Axovant Sciences purchased intellectual property rights to a leading Alzheimer's treatment currently in clinical trials.
http://seekingalpha.com/article/3246746-axova...-potential
They didn't mention that the purchase price was only 5 million dollars, because GSK decided it wasn't worth continuing to develop.